Chief Scientist

Azitra Inc.
Job Location
400 Farmington Ave
Farmington, CT 06032

3.6k annual stipend for healthcare


Job Description

Azitra is seeking a full-time Chief Scientist capable of driving forward experimental efforts as well as contributing to the broader scientific direction in the lab. The individual’s primary responsibility will be able to design and execute experiments in collaboration with Azitra's founders and scientific advisors. Self-starters and individuals seeking leadership and growth are a must.   

  • PhD in biological sciences (e.g., microbiology, cell biology, pathology)
  • Advanced skills in cloning techniques
  • Experience in bacterial transformation and protein expression
  • Experience with rodents
  • Experience with mammalian cell culture; specific experience with organotypic culture is highly desirable
  • Basic and advanced microscopy skills; specific experience with confocal microscopy and tissue sectioning is highly desirable
How to Apply
About Our Organization

Azitra is an early stage, biotechnology company focused on treating skin conditions by harnessing the power of the microbiome and synthetic biology to enable an innovative, inexpensive, and convenient treatment modality.

Current treatment options for a number of skin diseases generally aim for symptomatic relief and fail to address underlying pathophysiological changes leading to skin disease. In the case of genetic mutations that cause loss of function mutations, supplementation of the missing protein is a viable approach to treatment. However, delivery of functional protein to the target keratinocytes presents a significant challenge; moreover, the cost of protein production and purification creates a significant hurdle to developing a commercially viable treatment. Finally, given the natural turnover rate in the skin, constant reapplication of protein would be needed, which compounds issues related to cost of treatment, adherence, and convenience.

Azitra is a preclinical company focused on microbiome-based therapeutics. We are developing a platform that consists of an engineered S. epidermidis that is able to establish residence on human skin and secrete therapeutic protein in situ. An ointment with an inoculum of such bacteria could be infrequently applied to skin, providing constant, low-cost, convenient delivery of therapeutic protein. Our first candidate, AZT-01 aims to restore the skin barrier in atopic dermatitis patients by delivering a key skin protein involved in the disease pathology.

NIH's Michael Lauer looks at the number of grants, their amount, and funding success rates at the agency for last year.

At Nature, Johns Hopkins' Gundula Bosch describes her graduate program that aims to get doctoral students thinking about the big picture.

Patricia Fara writes about childcare funding, and women in science and science history at NPR.

National Institute of Environmental Health Sciences researchers have visualized the career paths of former postdocs.